• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Phase II study shows oral tazarotene treatment yields QOL benefits for sufferers of severe acne

Article

Washington D.C. ?? Patients with severe nodulocystic acne treated with oral tazarotene experience a substantial improvement in acne-specific health-related quality of life (HRQOL), according to the results of a Phase II dose-ranging study presented by Patricia S. Walker, M.D., Ph.D., at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content
Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Article
Jessner’s Lymphocytic Infiltration of the Skin Mimicking Rosacea: A Rare Case Presentation

Jessner’s Lymphocytic Infiltration of the Skin Mimicking Rosacea: A Rare Case Presentation

Article
© 2024 MJH Life Sciences

All rights reserved.